Glaxo Wellcome plc has made a major commitment to development of a novel treatment that, if successful, would be the first product for rheumatoid arthritis that would both affect the clinical course of the disease and reduce its symptoms.
British Biotech plc (BBIOY) and Glaxo Wellcome announced an agreement under which Glaxo will develop BBIOY’s BB-2983 as an oral treatment for rheumatoid arthritis. Glaxo will